SD 208

• Supplier: Tocris Bioscience
• Catalog: 3035
• Prices: $169.00, $705.00
• Sizes: 10 mg, 50 mg
• Function Type: Inhibitor
• Cas Number: 627536-09-8
• Chemical Name: 2-(5-Chloro-2-fluorophenyl)-4-[(4-pyridyl)amino]pteridine
• Formula: C17H10ClFN6
• Molecular Weight: 352.75
• Purity: >98 %
• Description: Potent, orally active ATP-competitive transforming growth factor- β receptor 1 (TGF- β RI) inhibitor (IC 50 = 49 nM). Displays > 100-fold and > 17-fold selectivity over TGF- β RII and other common kinases respectively. Exhibits anti-inflammatory and antitumor activity. Also promotes an antiglioma immune response. Ameliorates germinal matrix hemorrhage-induced neurological deficits in neonatal rats.

Product References

SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, - SD-208, a novel transforming growth factor beta receptor I kinase inhibitor,

Uhl M, Aulwurm S, Wischhusen J, Weiler M, Ma JY, Almirez R, Mangadu R, Liu YW, Platten M, Herrlinger U, Murphy A, Wong DH, Wick W, Higgins LS, Weller M. Cancer Res. 2004 Nov 1;64(21):7954-61.

Transforming growth factor-beta receptor type 1 (TGFbetaRI) kinase activity but - Transforming growth factor-beta receptor type 1 (TGFbetaRI) kinase activity but

Kapoun AM, Gaspar NJ, Wang Y, Damm D, Liu YW, O'young G, Quon D, Lam A, Munson K, Tran TT, Ma JY, Murphy A, Dugar S, Chakravarty S, Protter AA, Wen FQ, Liu X, Rennard SI, Higgins LS. Mol Pharmacol. 2006 Aug;70(2):518-31. Epub 2006 May 17.

Effect of transforming growth factor-beta receptor I kinase inhibitor - Effect of transforming growth factor-beta receptor I kinase inhibitor

Leung SY, Niimi A, Noble A, Oates T, Williams AS, Medicherla S, Protter AA, Chung KF. J Pharmacol Exp Ther. 2006 Nov;319(2):586-94. Epub 2006 Aug 3.

Inhibition of transforming growth factor-beta attenuates brain injury and - Inhibition of transforming growth factor-beta attenuates brain injury and

Manaenko A, Lekic T, Barnhart M, Hartman R, Zhang JH. Stroke. 2014 Mar;45(3):828-34.